Abstract:Paradoxically, aggregation of specific proteins is characteristic of many human diseases and aging, yet aggregates have increasingly been found to be unnecessary for initiating pathogenesis. Here we determined the NMR topology and dynamics of a helical mutant in a membrane environment transformed from the 125-residue cytosolic all-β MSP domain of vesicle-associated membrane protein-associated protein B (VAPB) by the ALS-causing P56S mutation. Despite its low hydrophobicity, the P56S major sperm protein (MSP) domain becomes largely embedded in the membrane environment with high backbone rigidity. Furthermore it is composed of five helices with amphiphilicity comparable to those of the partly-soluble membrane toxin mellitin and α-synuclein causing Parkinson's disease. Consequently, the mechanism underlying this chameleon transformation becomes clear: by disrupting the specific tertiary interaction network stabilizing the native all-β MSP fold to release previously-locked amphiphilic segments, the P56S mutation acts to convert the classic MSP fold into a membrane-active protein that is fundamentally indistinguishable from mellitin and α-synuclein which are disordered in aqueous solution but spontaneously partition into membrane interfaces driven by hydrogen-bond energetics gained from forming α-helix in the membrane environments. As segments with high amphiphilicity exist in all proteins, our study successfully resolves the paradox by deciphering that the proteins with a higher tendency to aggregate have a stronger potential to partition into membranes through the same mechanism as α-synuclein to initially attack membranes to trigger pathogenesis without needing aggregates. This might represent the common first step for various kinds of aggregated proteins to trigger familiar, sporadic and aging diseases. Therefore the homeostasis of aggregated proteins in vivo is the central factor responsible for a variety of human diseases including aging. The number and degree of the membrane attacks by aggregated proteins may act as an endogenous clock to count down the aging process. Consequently, a key approach to fight against them is to develop strategies and agents to maintain or even enhance the functions of the degradation machineries.

Aberrant protein aggregation in amyotrophic lateral sclerosis

Research Progress on Vesicular Trafficking in Amyotrophic Lateral Sclerosis.

Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis

Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS

Epigenetics in the formation of pathological aggregates in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

Autophagy and Its Comprehensive Impact on ALS

Novel therapeutic targets for amyotrophic lateral sclerosis: ribonucleoproteins and cellular autonomy

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights

The Essential And Downstream Common Proteins Of Amyotrophic Lateral Sclerosis: A Protein-Protein Interaction Network Analysis

Bioinformatics Analysis of Amyotrophic Lateral Sclerosis Associated Amino Acid Mutations

Dissecting How ALS-associated D290V Mutation Enhances Pathogenic Aggregation of Hnrnpa2286–291 Peptides: Dynamics and Conformational Ensembles

The Current Potential Pathogenesis of Amyotrophic Lateral Sclerosis

The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis

Protein aggregation and its affecting mechanisms in neurodegenerative diseases

Advancements in TDP-43 Research: Towards Biomarkers and Therapeutic Targets for Amyotrophic Lateral Sclerosis

Targeting Protein Aggregation in ALS

Resolving the paradox for protein aggregation diseases: NMR structure and dynamics of the membrane-embedded P56S-MSP causing ALS imply a common mechanism for aggregation-prone proteins to attack membranes

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Prion-Like Mechanisms in Parkinson’s Disease